×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Session 12: Clinical Trials & Pharmacovigilance
Session Chair(s)
Susan Kindig, JD, MD
Prior Executive Director, Medical and Drug Safety
United States
Barbara Hendrickson, DrMed, MD
Clinical Associate, Pediatric Infectious Diseases
University of Chicago, United States
This session will provide an introduction and overview of the newly-released FDA Draft Guidance on Use of Data Monitoring Committees (DMC) in clinical trials. Valuable practical information will be provided to enable safety professionals to better evaluate DMC charters and support the implementation of DMCs. In addition, the potential use of DMCs in IND reporting decisions for anticipated events in the study population will be discussed.
Learning Objective : - Understand the new FDA Draft Guidance published in Feb 2024, “Use of Data Monitoring Committees in Clinical Trials” (“DMC Draft Guidance”)
- Describe common misconceptions of DMCs and best practices for training of DMC members
Speaker(s)
Speaker
Representative Invited
FDA, United States
Speaker
Representative Invited
Duke Clinical Research Institute, Duke University Medical Center, United States